Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression
Open Access
- 7 May 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 691249
- https://doi.org/10.3389/fimmu.2021.691249
Abstract
Background: Dynamic D-dimer level is a key biomarker for the severity and mortality of COVID-19 (coronavirus disease 2019). How aberrant fibrinolysis influences the clinical progression of COVID-19 presents a clinicopathological dilemma challenging intensivists. Methods: We performed meta-analysis and meta regression to analyze the associations of plasma D-dimer with 106 clinical variables to identify a panoramic view of the derangements of fibrinolysis in 14,862 patients of 42 studies. There were no limitations of age, gender, race, and country. Raw data of each group were extracted separately by two investigators. Individual data of case series, median and interquartile range, and ranges of median or mean were converted to SDM (standard deviation of mean). Findings: The weighted mean difference of D-dimer was 0.97 g/mL (95% CI 0.65, 1.29) between mild and severe groups, as shown by meta-analysis. Publication bias was significant. Meta-regression identified 58 of 106 clinical variables were associated with plasma D-dimer levels. Of these, 11 readouts were negatively related to the level of plasma D-dimer. Further, age and gender were confounding factors. There were 22 variables independently correlated with the D-dimer level, including respiratory rate, dyspnea plasma K+, glucose, SpO2, BUN (blood urea nitrogen), bilirubin, ALT (alanine aminotransferase), AST (aspartate aminotransferase), systolic blood pressure, and CK (creatine kinase). Interpretation: These findings support elevated D-dimer as an independent predictor for both mortality and complications. The identified D-dimer-associated clinical variables draw a landscape integrating the aggregate effects of systemically suppressive and pulmonary hyperactive derangements of fibrinolysis, and the D-dimer-associated clinical biomarkers, and conceptually parameters could be combined for risk stratification, potentially for tracking thrombolytic therapy or alternative interventions.Funding Information
- National Heart, Lung, and Blood Institute
This publication has 91 references indexed in Scilit:
- D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applicationsCritical Reviews in Clinical Laboratory Sciences, 2018
- Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8Cytokine, 2018
- D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart DiseaseJournal of the American College of Cardiology, 2018
- Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysisOncotarget, 2017
- Fibrin Formation, Structure and PropertiesPublished by Springer Science and Business Media LLC ,2017
- Systematic review and meta-analysis of nasal potential difference in hypoxia-induced lung injuryScientific Reports, 2016
- Label-Free Kinetic Studies of Hemostasis-Related Biomarkers Including D-Dimer Using Autologous Serum TransfusionPLOS ONE, 2015
- D-dimerPublished by Elsevier BV ,2015
- Age- and sex-dependent reference intervals for D-dimer: Evidence for a marked increase by ageThrombosis Research, 2013
- Studies of the metabolism and distribution of fibrinogen in healthy men with autologous 125-I-labeled fibrinogen.JCI Insight, 1966